



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

## Journal of Cystic Fibrosis

journal homepage: [www.elsevier.com/locate/jcf](http://www.elsevier.com/locate/jcf)

## From the Editor's Desk

Another year has passed and the pandemic is still upon us. The CF community has demonstrated considerable innovation and resiliency in response to the threat of the novel coronavirus (SARS-CoV-2). I remain highly impressed at how the international CF community came together to share data as we learned about this virus [1]. Clinical care and research were disrupted [2], but we adapted, and those novel approaches to provision of care were shared in our pages. The delivery of care will be forever changed, mostly because of technology but the pandemic was the accelerant. This was described in greater detail in a supplement dedicated to the topic of the future of CF care [3] and we will need to continue to innovate, testing new methods in order to achieve the best for those we serve.

Despite the surges of the pandemic, the Journal of Cystic Fibrosis (JCF) and other journals continued to receive a large number of high quality CF-specific manuscripts, demonstrating that scholarly activities would not be denied. We include in this issue a review of CF highlights from the past year [4] to offer but a glimpse of some of the recent major advances in our knowledge. A testament to the high quality of manuscripts submitted to JCF is that we published more articles than any previous year and still had an increase in impact factor. The recently published papers with the greatest number of citations in 2021 are shown in Table 1. An

important observation is that all of these papers are available as Open Access, freely available to all readers. We appreciate that our publisher has worked with countries and institutions to enable authors to publish in this manner, with an increase in Open Access articles by >300 percent. As I have stated before, we do not assess our success by citations alone; our readership includes all members of the multidisciplinary team, persons with CF, and their families. They access JCF through downloads and social media citations, and downloads increased by more than 7% from the previous year.

We remain grateful to the Editorial Board and reviewers who contribute to the peer review processes so vital to JCF. They help us identify and improve the manuscripts that eventually find their way into JCF. We know that the editorial review process places great burden on the editors and reviewers. The editorial board is listed in the masthead of the journal and we include a complete list of all who performed at least one review for JCF in this issue [189–378]. Those individuals who performed at least five reviews are listed in Table 2, but we especially want to recognize Pierre-Regis Burgel (16), Bradley Quon (15), Jenna Sykes (9), Frank Bodewes (9), and Anne Stephenson (9) as our top five reviewers of 2021.

**Table 1**  
Top Ten Recent Manuscripts Cited in 2021.

Title	Type
*Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries [5]	Original article
*A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis [6]	Original article
*CFTR modulator theratyping: Current status, gaps and future directions [7]	Review
*Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease [8]	Original article
*Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines [9]	Review
*The global impact of SARS-CoV-2 in 181 people with cystic fibrosis [10]	Original article
*An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–57years (KLIMB) [11]	Original article
*Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis [12]	Review
*Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection [13]	Original article
*Predictive factors for lumacaftor/ivacaftor clinical response [14]	Original article

\*Open Access

**Table 2**  
Individuals who performed  $\geq 5$  reviews during 2021.

Pierre-Régis Burgel
Bradley Quon
Frank Bodewes
Jenna Sykes
Anne Stephenson
Peter Middleton
Sonya Heltshe
Tanja Gonska
Steven Taylor
Lucy Perrem
Jonathan D. Cogen
Ranjani Somayaji
Kathleen J. Ramos
Clement Ren
Scott C. Bell
Gregory S. Sawicki
Stephanie Van Biervliet
Francois Vermeulen
James F. Chmiel
Isabel Durieu
Stacey L. Martiniano
Edith T. Zemanick
Denis Hadjiliadis
Natalia Cirilli
Alvin Jay Freman
Jill Dorsey

Patrick A. Flume  
 Editor in Chief, Medical University of South Carolina, Charleston,  
 South Carolina, USA

## References

- [1] Bain R, Cosgriff R, Zampoli M, Elbert A, Burgel PR, Carr SB, et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study. *J Cyst Fibros* 2021;20:25–30.
- [2] Pearson K, Mayer-Hamblett N, Goss CH, Retsch-Bogart GZ, VanDalfsen JM, Burks P, et al. The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network. *J Cyst Fibros* 2021;20:195–7.
- [3] Impact of the COVID-19 Pandemic: how our response is shaping the future of cystic fibrosis care. *J Cyst Fibros* 2021(Suppl 3):S1–66.
- [4] Bihouee T, Barr H, Zwitsersloot AM. A year in review: real world evidence, functional monitoring and emerging therapeutic strategies in 2021. *J Cyst Fibros* 2022;21:191–6.
- [5] Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. *J Cyst Fibros* 2020;19:68–79.
- [6] Cosgriff R, Ahern S, Bell S, Browenlee K, Burgel PR, Byrnes C, et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. *J Cyst Fibros* 2020;19:355–8.
- [7] Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, et al. CFTR modulator therotyping: Current status, gaps and future directions. *J Cyst Fibros* 2019;18:22–34.
- [8] Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. *J Cyst Fibros* 2020;19:344–54.
- [9] Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. *J Cyst Fibros* 2019;18:321–33.
- [10] McClenaghan E, Cosgriff R, Borwnlee K, Ahern S, Burgel PR, Byrnes CA, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. *J Cyst Fibros* 2020;19:868–71.
- [11] Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelman WE, Sawicki GS, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB). *J Cyst Fibros* 2019;18:838–43.
- [12] Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R. Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. *J Cyst Fibros* 2019;18:S3–9.
- [13] Bentur L, Gur M, Ashkenazi M, Livnat-Levanon G, Mizrahi M, Tal A, et al. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. *J Cyst Fibros* 2020;19:225–31.
- [14] Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, et al. Predictive factors for lumacaftor/ivacaftor clinical response. *J Cyst Fibros* 2019;18:368–74.